-
EP1738759
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1738759
| EP1738759 - Inhibition of abnormal cell proliferation with camptothecin and combinations including the same [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.05.2008 Database last updated on 19.07.2024 | Most recent event Tooltip | 09.05.2008 | Application deemed to be withdrawn | published on 11.06.2008 [2008/24] | Applicant(s) | For all designated states SuperGen, Inc. 4140 Dublin Boulevard, Suite 200 Dublin, California 94568 / US | [2007/01] | Inventor(s) | 01 /
Rubinfeld, Joseph 5304 Blackhawk Drive Danville, CA 94506 / US | [2007/01] | Representative(s) | Gallagher, Kirk James, et al D Young & Co LLP 120 Holborn London EC1N 2DY / GB | [N/P] |
| Former [2007/01] | Gallagher, Kirk James, et al D Young & Co 120 Holborn London EC1N 2DY / GB | Application number, filing date | 06021027.5 | 19.04.2001 | [2007/01] | Priority number, date | US20000553710 | 20.04.2000 Original published format: US 553710 | [2007/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP1738759 | Date: | 03.01.2007 | Language: | EN | [2007/01] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 29.11.2006 | Classification | IPC: | A61K31/437, A61P35/00 | [2007/01] | CPC: |
A61K45/06 (EP,US);
A61K31/44 (EP,US);
A61K31/4745 (EP,US);
A61K31/70 (EP,US);
A61P35/00 (EP)
| C-Set: |
A61K31/44, A61K2300/00 (US,EP);
A61K31/4745, A61K2300/00 (EP,US);
A61K31/70, A61K2300/00 (US,EP)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2007/01] | Title | German: | Hemmung von abnormaler Zellvermehrung durch Camptothecin und Kombinationen dieses enthaltend | [2007/01] | English: | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | [2007/01] | French: | Inhibition de la prolifération cellulaire anormale avec de la camptothecine et des combinaisons contenant ledit composé | [2007/01] | Examination procedure | 18.10.2006 | Examination requested [2007/01] | 13.08.2007 | Despatch of a communication from the examining division (Time limit: M04) | 29.12.2007 | Application deemed to be withdrawn, date of legal effect [2008/24] | 25.01.2008 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2008/24] | Parent application(s) Tooltip | EP01930607.5 / EP1276479 | Fees paid | Renewal fee | 18.10.2006 | Renewal fee patent year 03 | 18.10.2006 | Renewal fee patent year 04 | 18.10.2006 | Renewal fee patent year 05 | 18.10.2006 | Renewal fee patent year 06 | 27.04.2007 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]US5786344 (RATAIN MARK J [US], et al) [X] 1-15,26-28 * see in particular examples 1, 2, 14, 15, 20, 24, 29; claims 1, 3, 10, 15-17, 24, 26 *; | [E]WO0128542 (SUPERGEN INC [US], et al) [E] 1-15,26-28 * see in particular the claims *; | [X] - GIOVANELLA B ET AL, "Treatment of human cancer xenografts with camptothecin analogues in combination with cytoxan or x-irradiation.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, 85th Annual Meeting of the American Association for Cancer Research;San Francisco, California, USA; April 10-13, 1994, 1994, (1994), vol. 35, ISSN 0197-016X, page 454, XP001064595 [X] 1,2,13-15,26-28 * see the abstract * | [X] - NAIK HARMESH ET AL, "Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.", UROLOGY, (1996), vol. 48, no. 3, ISSN 0090-4295, pages 508 - 511, XP001069434 [X] 1,2,13-15,26-28 * see in particular the abstract; figures 2 and 3; p. 511, left column - right column, first paragraph * DOI: http://dx.doi.org/10.1016/S0090-4295(96)00201-4 | [X] - CIESIELSKI M J ET AL, "Combination therapy with 9-aminocamptothecin (9-AC) and etoposide (VP-16) in human glioblastoma.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, (1996), vol. 37, ISSN 0197-016X, page 427, XP001068950 [X] 1,5,13-15,26-28 * see the abstract * | [X] - HORN L ET AL, "Cellular effects of 9-aminocamptothecin when combined with other chemotherapeutic agents.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, (199803), vol. 39, ISSN 0197-016X, page 526, XP001068951 [X] 1,2,4,13-15,26-28 * see the abstract * | [X] - ROTHENBERG M.L., "Topoisomerase I inhibitors: Review and update.", ANNALS OF ONCOLOGY, (1997), vol. 8, no. 9, pages 837 - 855, XP001069433 [X] 1-15,26-28 * see in particular p. 841, left column, 3rd paragraph; p. 843, table 4; p. 846, left column, first two paragraphs; p. 846, right column, last paragraph - p. 847, left column, first paragraph * DOI: http://dx.doi.org/10.1023/A:1008270717294 | [X] - SOLA FRANCESCO ET AL, "The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule.", CANCER CHEMOTHERAPY AND PHARMACOLOGY, (199903), vol. 43, no. 3, ISSN 0344-5704, pages 241 - 246, XP002104215 [X] 1,13-15,26-28 * see in particular the abstract; p. 242, left column, 1st paragraph; p. 245, table 4; p. 245, left column, last paragraph - p. 246, left column, 1st paragraph * DOI: http://dx.doi.org/10.1007/s002800050890 | [X] - O'LEARY JAMES J ET AL, "Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model", CLINICAL CANCER RESEARCH, ISSN: 1078-0432, (199901), vol. 5, no. 1, pages 181 - 187, XP001070226 [X] 1,5,13-15,26-28 * see in particular the abstract; p. 184, right column, l. 35-55; p. 185, table 1; p. 185, right column l. 9 - p. 186, right column, l. 2 * | by applicant | US4636195 | WO9001969 | WO9003768 | EP0383492 | US5049132 | US5286254 | US5429634 | US5464650 | US5527337 | EP0716836 | US5545208 | US5552154 | US5649977 | US5679400 | US5731316 | - WALL, M., "plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata", J. AM. CHEM. SOC., (1966), vol. 88, pages 3888 - 3890 | - "Camptothecin: Discovery to Clinic", MONROE E. WALL, 803 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1996), vol. 1 | - GOTTLIEB, J. A., "Preliminary pharmacological and clinical evaluation of camptothecin sodium salt (NSC 100880", CANCER CHEMOTHER. REP., (1979), vol. 54, pages 461 - 470 | - MUGGIA, F.M., "Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880): Correlation with clinical studies", CANCER CHEMOTHER. REP., (1972), vol. 56, pages 515 - 521 | - GOTTLIEB, J. A., "Treatment of malignant melanoma with camptothecin (NSC 100880", CANCER CHEMOTHER. REP., (1972), vol. 56, pages 103 - 105 | - MOERTEL, C.G., "Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer", CANCER CHEMOTHER REP., (1972), vol. 56, pages 95 - 101 | - GIOVANELLA, B. C., CANCER, (1983), vol. 52, no. 7, page 1146 | - GIOVANELLA, B.C., "Highly effective topoisomerase-I targeted chemotherapy of human colon cancer in xenografts", SCIENCE, (1989), vol. 246, pages 1046 - 1048 | - D. CHATTERJEE, "Induction of Apoptosis in Malignant and Camptothecin- resistant Human Cells", 803 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1996), vol. 143 | - FERRARA N.; ALITALO, K., "Clinical application of angiogenic growth factors and their inhibitors", NATURE MEDICINE, (1999), vol. 5, doi:doi:10.1038/70928, pages 1359 - 1364, XP002217702 DOI: http://dx.doi.org/10.1038/70928 | - LANGE, SCIENCE, (199009), vol. 249, pages 1527 - 1533 | - MATHIOWITZ, J. APP. POLY SCI., (1981), vol. 26, page 809 | - LANGE, SCIENCE, vol. 249, pages 1527 - 1533 |